Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity

Journal:
Science Advances
Published:
DOI:
10.1126/sciadv.adx3959
Affiliations:
8
Authors:
27
Go to article
Institutions Authors Share
Genentech, Inc., United States of America (USA)
23.000000
23.000000
23.000000
 0.85
Roche, Switzerland
3.000000
 0.11
Hoffmann-La Roche Ltd., Canada
1.000000
 0.04
Interested in Biochemistry and Cell Biology?